Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer

PURPOSE: The aim of this study was to identify factors associated with progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC) treated with eribulin in a real-world setting, to improve information provision in those considering treatment. METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Coe, Faye, Misra, Vivek, McCabe, Yamini, Adderley, Helen, Woodhouse, Laura, Ayub, Zaheen, Wang, Xin, Howell, Sacha, Ekholm, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831340/
https://www.ncbi.nlm.nih.gov/pubmed/34843027
http://dx.doi.org/10.1007/s10549-021-06438-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831340/
https://www.ncbi.nlm.nih.gov/pubmed/34843027
http://dx.doi.org/10.1007/s10549-021-06438-7

Ejemplares similares